Introduction/Background Population-based screening that starts at the age of 30 and ends at the age of 65 is applied, and HPV DNA screening is not recommended under the age of 30 in our country. For this reason, in this study, we analyze our patients aged 25–30 years who underwent colposcopy in detail and discuss the possible benefits of HPV screening in this group.

Methodology Patients aged 25–30 years who applied to the Department of Gynecological Oncology, University of Health Sciences, Zeynep Kamil Women and Children’s Diseases Training and Research Hospital due to abnormal Pap smear and/or yr-HPV type(s) positivity, were included in the study. Patients who had previously undergone colposcopy or a diagnostic excisional procedure were excluded from the study. Statistical analysis was performed using IBM SPSS for Windows, Version 25.0. (IBM Corp., Armonk, NY, USA).

Results A total of 201 patients, 86 (42.8%) with normal cytology and 115 (57.2%) patients with abnormal cytology were included in the study. The cytology results of 42.8% of the patients were normal. HPV positivity was also present in 81.1% of the patients. CIN2 was detected in 17.9% of patients and CIN 3 was detected in 11% of patients in cervical biopsies, and loop electrosurgical excision procedure (LEEP) was performed in 10.5% of patients and cold knife conization (CKC) in 11.4%. There was a significantly higher rate of HPV negative (0.005) and a higher rate of benign colposcopic biopsy results (< 0.001) in the cytology normal group. Detailed analysis results are given in table 1.

Conclusion The rates of CIN2 and CIN3 between normal cytology and abnormal cytology groups were similar. Colposcopy could be recommended to detect high-grade lesion in 25–30-year-old women with normal cytology and HPV positive.

Disclosures The authors have no potential conflict of interest.